English, Article edition: Warfarin in the Secondary Prevention of Thromboembolism in Atrial Fibrillation: Impact of Bioavailability on Costs and Outcomes Nicole Mittmann; Paul I. Oh; Scott E. Walker; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/119699
Physical Description
  • article
Language
  • English

Edition details

Title
  • Warfarin in the Secondary Prevention of Thromboembolism in Atrial Fibrillation: Impact of Bioavailability on Costs and Outcomes
Author
  • Nicole Mittmann
  • Paul I. Oh
  • Scott E. Walker
  • William R. Bartle
Physical Description
  • article
Notes
  • Background: The bioavailability of warfarin is an important factor affecting the achievement of therapeutic anticoagulation. It is uncertain whether less expensive generic preparations of warfarin would compromise prevention of thromboembolism or increase bleeding risk in patients with atrial fibrillation. Objective: To compare the cost effectiveness of strategies using warfarin products with variable bioavailability in patients with a prior stroke or transient ischaemic attack related to atrial fibrillation. Design: A Markov decision-analytic model simulating health and economic outcomes over 1 year using the perspective of a government provincial payer was created. Four strategies were compared (where F =​ 1 is the assumed bioavailability of the branded/​reference product): (i) warfarin F =​ 1; (ii) warfarin F =​ 1.25; (iii) warfarin F =​ 0.80; and (iv) alternating warfarin F =​ 1.25 and 0.80 every other month. Direct medical costs for drugs, physician fees, laboratory testing and hospitalisation for morbid events were obtained from a government payer, a local accounting system and the medical literature. The cost of warfarin F =​ 1 was equivalent to the cost of the brand name warfarin and the cost of warfarin F Results: In our institution, warfarin F =​ 1 was similar in cost to the other three strategies ($Can1361 vs $Can1334-1613) and may be more effective than switching between generic preparations which have bioavailabilities at the extremes of acceptable limits (thromboembolism and bleeds 7. 1% vs 9.3%). Conclusions: In patients with atrial fibrillation and a prior ischaemic stroke or transient ischaemic attack, the use of one warfarin agent within the range of acceptable bioavailability can be considered economically attractive from the healthcare perspective.
  • Anticoagulants, Anticoagulants, Atrial-fibrillation, Cost-effectiveness, Thromboembolism, Warfarin, Warfarin
  • RePEc:wkh:phecon:v:22:y:2004:i:10:p:671-683
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment